Processa Pharmaceuticals Financials
| PCSA Stock | USD 2.22 0.07 3.06% |
Processa Pharmaceuticals Balance Sheet Chart
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | 1.1 |
|
|
The essential information of the day-to-day investment outlook for Processa Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should research Processa Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Processa Pharmaceuticals.
Net Income |
|
Processa | Select Account or Indicator | Build AI portfolio with Processa Stock |
Please note, the presentation of Processa Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Processa Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Processa Pharmaceuticals' management manipulating its earnings.
Processa Pharmaceuticals Stock Summary
Processa Pharmaceuticals competes with Briacell Therapeutics, Curis, Palisade Bio, Hoth Therapeutics, and Moleculin Biotech. Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. The company was incorporated in 2011 and is based in Hanover, Maryland. Processa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US74275C2052 |
| Business Address | 7380 Coca Cola |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.processapharmaceuticals.com |
| Phone | 443 776 3133 |
| Currency | USD - US Dollar |
Processa Pharmaceuticals Key Financial Ratios
| Return On Equity | -2.71 | ||||
| EBITDA | (12.05 M) | ||||
| Net Income | (11.85 M) | ||||
| Cash Per Share | 0.76 X | ||||
| Debt To Equity | 0 % |
Processa Pharmaceuticals Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 26.5M | 8.6M | 5.8M | 3.2M | 3.7M | 3.5M | |
| Other Current Liab | 681.0K | 592.1K | 335.3K | 578.7K | 665.5K | 383.2K | |
| Net Debt | (16.4M) | (6.3M) | (4.6M) | (1.1M) | (1.0M) | (1.1M) | |
| Retained Earnings | (36.8M) | (64.2M) | (75.4M) | (87.2M) | (78.5M) | (74.6M) | |
| Cash | 16.5M | 6.5M | 4.7M | 1.2M | 1.4M | 1.3M | |
| Total Liab | 978.4K | 1.1M | 797.5K | 1.5M | 1.4M | 1.5M | |
| Total Current Assets | 18.3M | 8.4M | 5.6M | 1.9M | 2.2M | 2.0M | |
| Short Term Debt | 71.1K | 78.9K | 83.6K | 73.0K | 65.7K | 62.4K | |
| Common Stock | 1.6K | 1.6K | 129.0 | 371.0 | 426.65 | 405.32 | |
| Accounts Payable | 218.9K | 327.5K | 311.6K | 880.9K | 1.0M | 1.1M | |
| Other Current Assets | 1.8M | 1.9M | 926.3K | 682.3K | 784.6K | 578.1K | |
| Net Invested Capital | 25.5M | 7.5M | 5.0M | 1.7M | 1.5M | 1.5M | |
| Net Working Capital | 17.4M | 7.4M | 4.9M | 341.0K | 392.1K | 372.5K | |
| Capital Stock | 1.6K | 1.6K | 129.0 | 371.0 | 333.9 | 317.21 |
Processa Pharmaceuticals Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Interest Expense | 36.7K | 281.1K | 362.0 | 101.2K | 91.1K | 99.5K | |
| Gross Profit | (875.3K) | (874.0K) | (222.0) | (782.0) | (703.8) | (738.99) | |
| Operating Income | (12.1M) | (27.5M) | (11.5M) | (12.1M) | (10.8M) | (10.3M) | |
| Ebit | (11.6M) | (20.3M) | (11.5M) | (12.1M) | (10.8M) | (10.3M) | |
| Research Development | 6.9M | 11.5M | 5.8M | 7.3M | 8.4M | 8.8M | |
| Ebitda | (10.8M) | (19.5M) | (11.5M) | (12.1M) | (10.8M) | (10.3M) | |
| Cost Of Revenue | 875.3K | 874.0K | 222.0 | 782.0 | 899.3 | 854.33 | |
| Income Before Tax | (12.0M) | (27.4M) | (11.1M) | (11.9M) | (10.7M) | (11.2M) | |
| Net Income | (11.4M) | (27.4M) | (11.1M) | (11.9M) | (10.7M) | (11.2M) | |
| Income Tax Expense | (1.0M) | (530.6K) | 27.4M | (2.0) | (2.3) | (2.18) | |
| Net Interest Income | 11.6K | 101.2K | 326.6K | 201.1K | 231.3K | 242.8K | |
| Interest Income | 12.0K | 101.2K | 326.6K | 201.1K | 231.3K | 242.8K |
Processa Pharmaceuticals Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Free Cash Flow | (8.7M) | (9.6M) | (8.1M) | (11.2M) | (10.1M) | (9.6M) | |
| Net Income | (11.4M) | (27.4M) | (11.1M) | (11.9M) | (10.7M) | (11.2M) | |
| Change In Cash | 1.1M | (10.0M) | (1.8M) | (3.5M) | (3.2M) | (3.0M) | |
| Other Non Cash Items | 220.6K | 7.7M | 1.4M | 87.2K | 100.3K | 95.2K | |
| End Period Cash Flow | 16.5M | 6.5M | 4.7M | 1.2M | 1.4M | 1.3M | |
| Depreciation | 791.0K | 788.5K | 222.0 | 782.0 | 899.3 | 854.33 |
Processa Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Processa Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Processa Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Processa Pharmaceuticals competition to find correlations between indicators driving Processa Pharmaceuticals's intrinsic value. More Info.Processa Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Processa Pharmaceuticals' Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Processa Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Most indicators from Processa Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Processa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 72.68, whereas Selling General Administrative is forecasted to decline to about 3 M.
| 2023 | 2024 | 2025 | 2026 (projected) | Total Operating Expenses | 11.5M | 12.1M | 13.9M | 7.3M | Cost Of Revenue | 222.0 | 782.0 | 899.3 | 854.33 |
Processa Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Processa Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Processa Pharmaceuticals fundamental ratios Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 26.5M | 8.6M | 5.8M | 3.2M | 3.7M | 3.5M | |
| Other Current Liab | 681.0K | 592.1K | 335.3K | 578.7K | 665.5K | 383.2K | |
| Net Debt | (16.4M) | (6.3M) | (4.6M) | (1.1M) | (1.0M) | (1.1M) | |
| Retained Earnings | (36.8M) | (64.2M) | (75.4M) | (87.2M) | (78.5M) | (74.6M) | |
| Cash | 16.5M | 6.5M | 4.7M | 1.2M | 1.4M | 1.3M | |
| Total Liab | 978.4K | 1.1M | 797.5K | 1.5M | 1.4M | 1.5M | |
| Total Current Assets | 18.3M | 8.4M | 5.6M | 1.9M | 2.2M | 2.0M | |
| Short Term Debt | 71.1K | 78.9K | 83.6K | 73.0K | 65.7K | 62.4K | |
| Common Stock | 1.6K | 1.6K | 129.0 | 371.0 | 426.65 | 405.32 | |
| Accounts Payable | 218.9K | 327.5K | 311.6K | 880.9K | 1.0M | 1.1M | |
| Other Current Assets | 1.8M | 1.9M | 926.3K | 682.3K | 784.6K | 578.1K | |
| Net Invested Capital | 25.5M | 7.5M | 5.0M | 1.7M | 1.5M | 1.5M | |
| Net Working Capital | 17.4M | 7.4M | 4.9M | 341.0K | 392.1K | 372.5K | |
| Capital Stock | 1.6K | 1.6K | 129.0 | 371.0 | 333.9 | 317.21 |
Today, most investors in Processa Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Processa Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Processa Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Processa Pharmaceuticals February 16, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Processa Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Processa Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Processa Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Processa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Processa Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 164.28 | |||
| Value At Risk | (14.08) | |||
| Potential Upside | 10.24 |
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |